ContextLogic Inc (LOGC)
NASDAQ: LOGC · IEX Real-Time Price · USD
6.00
-0.03 (-0.50%)
At close: Jul 19, 2024, 12:00 AM
5.94
-0.06 (-1.00%)
Pre-market: Jul 22, 2024, 9:05 AM EDT
ContextLogic Employees
ContextLogic had 452 employees as of December 31, 2023. The number of employees decreased by 434 or -48.98% compared to the previous year.
Employees
452
Change (1Y)
-434
Growth (1Y)
-48.98%
Revenue / Employee
$502,212
Profits / Employee
-$634,956
Market Cap
146.95M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 452 | -434 | -48.98% |
Dec 31, 2022 | 886 | -332 | -27.26% |
Dec 31, 2021 | 1,218 | 343 | 39.20% |
Dec 31, 2020 | 875 | 123 | 16.36% |
Dec 31, 2019 | 752 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Tilly's | 6,048 |
The ONE Group Hospitality | 5,000 |
Purple Innovation | 1,700 |
Kewaunee Scientific | 1,006 |
Kandi Technologies Group | 840 |
Niu Technologies | 550 |
Innoviz Technologies | 488 |
GrowGeneration | 400 |
LOGC News
- 1 year ago - Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics - Business Wire
- 1 year ago - LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates - PRNewsWire
- 1 year ago - LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC - Business Wire
- 1 year ago - INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGC - PRNewsWire
- 1 year ago - SHAREHOLDER ALERT: Weiss Law Investigates LogicBio Therapeutics, Inc. - PRNewsWire
- 1 year ago - Shareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its transaction with AstraZeneca - PRNewsWire
- 1 year ago - LogicBio's stock skyrockets after buyout bid for a 667% premium - Market Watch
- 1 year ago - LOGC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LogicBio Therapeutics, Inc. Is Fair to Shareholders - Business Wire